本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Enanta Pharmaceuticals Inc.

7.51
+0.05000.67%
成交量:11.33万
成交额:86.29万
市值:1.61亿
市盈率:-1.74
高:7.81
开:7.42
低:7.42
收:7.46
52周最高:13.37
52周最低:4.09
股本:2,137.79万
流通股本:1,424.76万
量比:0.60
换手率:0.79%
股息:- -
股息率:- -
每股收益(TTM):-4.3219
每股收益(LYR):-5.4849
净资产收益率:-80.64%
总资产收益率:-17.29%
市净率:2.03
市盈率(LYR):-1.37

数据加载中...

公司资料

公司名字:
Enanta Pharmaceuticals Inc.
交易所:
NASDAQ
成立时间:
1995
员工人数:
131
公司地址:
4 Kingsbury Avenue,Watertown,Massachusetts,United States
邮编:
02472
电话:
传真:
617 607 0530
简介:
Enanta Pharmaceuticals, Inc.于1995年根据特拉华州法律注册成立。该公司是一家生物技术公司,利用稳健、化学驱动的方法和药物发现能力,成为小分子药物发现和开发的领导者,重点是病毒感染的治疗。该公司发现了gleCAPrevir,这是通过与艾伯维合作发现和开发的两种蛋白酶抑制剂中的第二种,用于治疗丙型肝炎病毒(HCV)的慢性感染。

董事

名称
职位
Bruce L. A. Carter
Director and non-executive Chairman of the Board
Jay R. Luly
President, Director and Chief Executive Officer
Kathleen S. Capps
Executive Director, Accounting, Controller and Interim Principal Accounting Officer
Kristine Peterson
Director
Lesley Russell
Director
Mark G. Foletta
Director
Terry Vance
Director
Yujiro S. Hata
Director

股东

名称
职位
Jay R. Luly
President, Director and Chief Executive Officer
Brendan Luu
Chief Business Officer
Harry R. Trout, III
Vice President, Finance and Interim Principal Financial Officer
Kathleen S. Capps
Executive Director, Accounting, Controller and Interim Principal Accounting Officer
Matthew P. Kowalsky
Chief Legal Officer and Corporate Secretary
Paul J. Mellett
Chief Financial and Administrative Officer
Scott T. Rottinghaus
Chief Medical Officer
Tara L. Kieffer
Chief Product Strategy Officer
Yat Sun Or
Chief Scientific Officer